Avatrombopag maleate is primarily used in the treatment of thrombocytopenia, a condition characterized by abnormally low levels of platelets in the blood. It is specifically indicated for patients with chronic liver disease who are scheduled to undergo a medical or dental procedure, as these patients are at a higher risk of bleeding due to low platelet counts. The drug works by stimulating the production of platelets in the bone marrow, thereby reducing the risk of bleeding during and after the procedure.

Additionally, avatrombopag maleate is used in the management of chronic immune thrombocytopenia (ITP) in patients who have had an insufficient response to other treatments. In this context, it helps to increase platelet counts to a level that reduces the risk of spontaneous bleeding.

The drug is typically administered orally, making it convenient for outpatient use. Its efficacy and safety profile have been established through clinical trials, making it a reliable option for patients with these specific conditions.